ElectroCore's Non-invasive Nerve Stimulator Effective Against Migraine

ElectroCore Inc ECOR announced the publication of a peer-reviewed paper entitled "Non-invasive vagus nerve stimulation (nVNS) for the prevention of migraine" in Cephalalgia, the official journal of the International Headache Society.

  • The paper reports the results of a randomized, double-blind, sham-controlled trial of gammaCore. 
  •  Originally designed to randomize 400 patients, the study was closed early due to COVID-19 after enrolling 231 subjects.
  • Related: ElectroCore Stock Is Trading Higher As Ladenburg Initiates Coverage With $3 Price Target, Buy Rating.
  • gammaCore is a non-invasive, hand-held medical therapy applied at the neck as adjunctive therapy to treat migraine and cluster headache by utilizing a mild electrical stimulation to the vagus nerve that passes through the skin. 
  • The study results showed a decrease in the number of monthly headache days of 4.6 vs. -3.0 for sham (p=0.05).
  • 44.87% of subjects in the gammaCore group had more than a 50% reduction in migraine days per month compared with 26.81% for the sham group (p=0.05). 
  • Quality of life improved by -4.9 points vs. -2.3 for sham (p<0.05). 
  • In the subpopulation of patients diagnosed with migraine with aura, the number of headache days decreased by 5.5 days in the nVNS group compared with 2.7 in the sham group (p=0<0.05), a therapeutic gain of >100% compared to sham. 
  • Price Action: ECOR shares closed 4.21% higher at $0.56 during after-hours trading on Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPenny StocksHealth CareGeneralBriefsmigraine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!